Pediatricians and family physicians surveyed by researchers from the University of Rochester Medical Center support expanding flu vaccination to healthy infants and toddlers. The study found that 58% of doctors would favor this expansion, despite citing high costs and parental concerns about vaccine safety as major barriers.
The NIAID Pandemic Influenza Preparedness Program supports the development and production of a candidate vaccine against H9N2 avian influenza. The vaccine will be produced by Chiron Corporation in Italy, with different dosages containing an adjuvant to boost its protective effect.
A study found that adults with regular doctors were more likely to receive influenza vaccinations and mammography, as well as advice on smoking cessation. This suggests that trust in a single provider contributes to better adherence to health recommendations.
A study led by Baylor College of Medicine and the University of Rochester Medical Center is testing a vaccine against H9 bird flu, which infected several people in Hong Kong in 1999. The goal is to prepare for potential transmission of the virus from person to person.
Using targeted antiviral prophylaxis (TAP) on close contacts of suspected flu cases can effectively contain an epidemic, with only 2% of the population becoming ill and a death rate of 0.04 per 1,000 people. TAP is nearly as effective as vaccinating 80% of the entire population, especially when used for eight weeks.
A new protein called VLA-1 enables the immune system to develop peripheral immunity by anchoring virus-killing cells to tissues in the lungs. This allows for an instant strike against flu viruses, potentially delivering a better defense against deadly strains like avian flu.
The study found that inactivated influenza virus vaccines are effective in protecting children against the flu, reducing hospitalization rates comparable to those of elderly people. Vaccinating children can also protect adults from getting infected and save money on treatment costs.
Researchers are testing a new flu vaccine that delivers the vaccine in the nose to observe differences in immune system reactions. The study aims to improve immunity in the respiratory tract for all pathogens, with implications for biodefense.
Recent studies suggest that pediatric influenza is a significant medical problem, causing excess hospitalizations and antibiotic prescriptions. Experts call for increased efforts to identify and vaccinate high-risk children, as well as educating parents and physicians about the importance of flu vaccination.
This year's flu season is severe due to a mutated virus that has changed slightly since last year's vaccine was designed. Young children are at higher risk of getting seriously ill as they haven't encountered the virus before and lack immunity. Experts recommend vaccinating all children aged 6 months to 23 months to prevent complications.
A nasal spray flu vaccine has been shown to be effective in preventing acute respiratory illness in all age groups. The vaccine was found to be particularly effective in preventing natural influenza A (H1N1) infection among children aged 5-9 years during the 2000-2001 epidemic.
Research found a 10-20% point gap in vaccination rates between blacks and whites, even after adjusting for socioeconomic factors. The study suggests that culturally appropriate messages and additional resources are needed to improve flu vaccination rates among underserved communities.
A study found that patient and doctor attitudes play a crucial role in influenza vaccination rates among older adults. A vaccination-friendly culture at veterans' hospitals exceeded the national goal of 90%, highlighting the importance of promoting preventive measures.
St. Jude experts highlight US vaccine production inadequacies and antiviral drug scarcity in responding to an outbreak, emphasizing the need for new technologies, international cooperation, and rapid testing.
A study by Ohio State University researchers found that even mild depression in caregivers can lead to increased inflammation, which is associated with various age-related illnesses. Chronic inflammation has been linked to declines in physical function and an increased risk of mortality.
A study published in the Proceedings of the National Academy of Sciences found that individuals with greater activity in the left side of the prefrontal cortex had a stronger immune response against disease. The researchers measured brain activity and immune function in 52 individuals between 57-60 years old, and found a positive corre...
Researchers created a technique using validation sets to verify epidemiological data, enhancing vaccine effectiveness studies. This approach helps address reporting bias and improves the reliability of many vaccine research outcomes.
The revised standards recommend systems to remind physicians and patients of immunization due dates, regular monitoring of immunization rates, and financial aid for those who cannot afford vaccination costs. These strategies aim to improve childhood and adult immunization coverage.
A new study shows that a derivative of green algae Chlorella pyrenoidosa improves the body's immune response to influenza vaccines. The study found significant increases in antibody responses after supplementation with two different doses of the extract, with no adverse effects reported.
A recent study published in the Canadian Medical Association Journal investigated the effects of a Chlorella-derived dietary supplement on immune function and influenza vaccination. The results showed no significant increase in antibody response to the flu vaccine overall, although some increase was seen in participants aged 50 to 55.
Researchers have identified the crucial elements of the flu virus that activate the body's T-cells, enabling a new type of vaccine to be developed. This breakthrough could provide long-term protection against future pandemics.
A novel flu vaccine developed by The Wistar Institute has generated a strong antibody response in mice, offering hope for a more stable and effective vaccine. The vaccine targets a stable region of the virus, potentially providing long-term protection against flu strains.
The Prevnar vaccine, developed at the University of Rochester, has shown remarkable real-world effectiveness in reducing invasive pneumococcal infections by 69% among children under two years old. This translates to approximately 20,000 fewer cases of infection each year in the United States.
The St. Jude team successfully developed a custom-made vaccine against the H5N1 flu virus in just four weeks, thanks to a modified technique called reverse genetics. The vaccine was created by mixing genes from H5N1 with those from a common flu virus, making it safe for human use.
The study found that vaccinated elderly patients were 48% less likely to die during the 1998-99 season and 50% less likely to die during the 1999-2000 season. Additionally, vaccinated patients were less likely to develop pneumonia, cardiac disease, and stroke, confirming previous VA research on flu shots' life-saving benefits.
Researchers found that mindfulness meditation increased activity in the left side of the frontal region, associated with lower anxiety and a more positive emotional state. The meditation group also showed a significantly larger increase in immune function compared to the control group.
The Jordan Report 20th Anniversary outlines significant advancements in vaccine research for diseases like HIV/AIDS, tuberculosis, malaria, and bioterrorism threats. The report emphasizes the importance of vaccines in preventing illness and death from infectious diseases.
A Stanford researcher found that vaccinating the entire population and using antiviral medications on those who get sick benefits society. The study found vaccination strategies were optimal in 95% of runs, with treatment of flu patients also benefiting 85% of the time.
Dr. Poland urges healthcare providers to improve influenza vaccination rates among the elderly, citing decades-long progress as 'unacceptably slow.' He proposes several strategies to achieve universal vaccination, including standing-order programs and reimbursement by Medicare.
The National Institute of Allergy and Infectious Diseases (NIAID) has expanded its vaccine testing network, which has been a national resource for vaccine development since 1962. The new network will test vaccines against potential agents of bioterrorism and assess emerging hypotheses about vaccine-related adverse side effects.
Researchers at Princeton University developed a mathematical method to predict the coming year's flu strain based on previous years' genetic sequences. The approach identified clusters of genetically similar viruses that tend to dominate in each season, with an accuracy rate comparable to existing methods.
A study by René Verreault and colleagues found that past vaccine exposure was associated with a reduced risk of developing Alzheimer's disease. The researchers used multivariate logistic regressions to compare vaccinated and non-vaccinated subjects, adjusting for age, sex, and education.
A new study is testing a diluted form of the traditional smallpox vaccine, aiming to increase available doses. Participants will receive either the full or reduced dose and be monitored for signs of successful vaccination.
Residents from rural areas are less likely to receive preventive health services compared to urban residents, largely due to limited access to healthcare facilities, specialists, and insurance. Cultural factors such as traditional values and reluctance to seek medical care may also contribute to this disparity.
A randomized trial shows that computer reminders can significantly boost vaccination rates for hospitalized patients, particularly those over 65. The system identified eligible candidates and prompted physicians to order vaccinations, resulting in a 51% increase in influenza vaccinations and a 36% increase in pneumonia vaccinations.
A Canadian Medical Association Journal article explores the pros and cons of Ontario's no-cost flu vaccine program, which aims to ease pressure on emergency services. Experts argue that while the program may be a step forward in influenza control, its effectiveness and cost-effectiveness are uncertain.
A study found that inactivated flu vaccine (TIV) was associated with lower health care visits and hospitalizations for pneumonia and influenza compared to the intranasal live attenuated influenza vaccine (LAIV) among US military personnel. TIV may be more effective than LAIV in preventing morbidity in highly immunized adult populations.
A study found that concerns about unknown ingredients, inconvenience, and previous side effects are major barriers to flu immunization. Addressing these concerns through outreach efforts and physician-patient interactions can increase vaccination rates in low-income populations.
A recent study from Ohio State University found that stress levels can weaken the immune system's response to pneumonia vaccinations. After six months, vaccinated individuals who were highly stressed showed a weaker immune response compared to those with lower stress levels.
A University of Michigan professor suggests that flu vaccines should be administered when available to prevent lost work days and reduce physician visits, even if not cost-effective for working adults. The vaccine may have a greater impact on the elderly, who are more prone to complications.
A DNA-based flu vaccine has shown promising results in a mouse study, generating high levels of neutralizing antibodies and providing protection at a lower dose. The vaccine combines C3d with HA glycoprotein, priming the immune system against influenza.
The nasal spray flu vaccine protected young children against the A/Sydney flu strain with an 86% efficacy rate, reducing disease severity and middle-ear infections. The two-year study showed overall protection of 92% and significant cross-protection against other strains.
A new study found that flu in children results in substantial use of outpatient medical resources, including 10 physician visits and over half resulting in antibiotic prescriptions. The study suggests that recommending an annual flu vaccine for all children could be a cost-effective national policy.
A University of Iowa study found that nearly 70% of older Iowans received the flu vaccine, but only about half got the pneumococcal vaccine. The researchers identified factors such as age, marital status, and access to healthcare as associated with vaccination rates.
A new study by University of Michigan professor Dr. Arnold S. Monto found that zanamivir, an antiviral drug, is 67% effective in preventing laboratory-confirmed clinical influenza infection. The drug was also shown to be 84% effective in preventing laboratory-confirmed illnesses with fever.
A study conducted in India found that pneumococcal serotypes 1, 6, 19, and others were commonly prevalent, with type-1 found in 25% of cases. The researchers also discovered high rates of antibiotic resistance among S. pneumoniae, particularly in urban areas.
A new study found that women under 65 with certain chronic medical conditions experience substantial morbidity and mortality from acute cardiopulmonary events during influenza season. The study suggests that stronger efforts to reach younger high-risk patients are needed to improve influenza vaccination levels.
Healthcare professionals who received the flu vaccine lost significantly fewer days of work due to illness compared to those who did not receive the vaccine. The vaccine also reduced the rate of influenza type A and B infections among vaccinated individuals.
A new nasal spray vaccine, FluMist(TM), has shown promising results in preventing the flu and flu-related ear infections in children. The vaccine provided 93% protection against the flu and 98% protection against otitis media, a common complication of the flu.
A new intranasal influenza vaccine has been shown to provide 93% protection against the flu in healthy young children. The vaccine was well-tolerated and safe for administration in a nasal spray format, offering an attractive alternative to traditional injection-based vaccines.
A new nasal flu vaccine has delivered good antibody responses and proven safe in children, offering a potential solution to stop the spread of the disease. The vaccine's effectiveness is now being analyzed in a larger study, which may lead to FDA approval starting in 1999.